Compare NVNO & MLEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVNO | MLEC |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.0M |
| IPO Year | 2017 | 2022 |
| Metric | NVNO | MLEC |
|---|---|---|
| Price | $8.86 | $4.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.0K | ★ 20.6K |
| Earning Date | 10-30-2026 | 10-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,243.00 | N/A |
| Revenue This Year | N/A | $20.42 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.21 |
| 52 Week High | $13.44 | $23.22 |
| Indicator | NVNO | MLEC |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | N/A |
| Support Level | $8.84 | N/A |
| Resistance Level | $11.47 | N/A |
| Average True Range (ATR) | 0.62 | 0.00 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 60.12 | 0.00 |
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.